Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03783-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Wenyu Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tok…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Chromosomes, Human, Pair 8, Translocation, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research on Innovative Areas, JSPS KAKENHI.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1);RUNX1-ETO is one of the most common subtypes of AML. Although t(8;21) AML has been classified as favorable-risk, only about half of patients are cured with current therapies. Several genetic abnormalities, including TP53 mutations and deletions, negatively impact survival in t(8;21) AML. In this study, we established Cas9 + mouse models of t(8;21) AML with intact or deficient Tpr53 (a mouse homolog of TP53 ) using a retrovirus-mediated gene transfer and transplantation system. Trp53 deficiency accelerates the in vivo development of AML driven by RUNX1-ETO9a, a short isoform of RUNX1-ETO with strong leukemogenic potential. Trp53 deficiency also confers resistance to genetic depletion of RUNX1 and a TP53-activating drug in t(8;21) AML. However, Trp53 -deficient t(8;21) AML cells were still sensitive to several drugs such as dexamethasone. Cas9 + RUNX1-ETO9a cells with/without Trp53 deficiency can produce AML in vivo, can be cultured in vitro for several weeks, and allow efficient gene depletion using the CRISPR/Cas9 system, providing useful tools to advance our understanding of t(8;21) AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
- Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. goyama@edu.…
Förderung
- Grant-in-Aid for Scientific Research (B)
- Grant-in-Aid for Scientific Research on Innovative Areas
- JSPS KAKENHI
- AMED
- The University of Tokyo
Zitieren
APA
Zhang, W., Li, J., Yamamoto, K., & Goyama, S. (2024). Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03783-3
Vancouver
Zhang W, Li J, Yamamoto K, Goyama S. Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03783-3
BibTeX
@article{Zhang2024,
author = {Zhang, Wenyu and Li, Jingmei and Yamamoto, Keita and Goyama, Susumu},
title = {Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03783-3}
}
EUVIMED